Celebrity Inventors
Comic actor Danny Kaye received patent D166,807 for the co-design of "Blowout Toy or the Like". It's similar to one of those toys that unravels when you blow into at a birthday party except Kaye's has three blowouts going in different directions, not just one.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173384 | Methods for analyzing or processing a heparin sample The invention relates to methods and products for analyzing or processing a heparin sample. In one embodiment, the methods comprise contacting the sample with heparinase I, heparinase II and heparinase III, determining the amount of a signature component in the samp... | 05/08/2012 |
| 8163513 | Method for determining the total clotting activity of a blood or plasma sample The invention relates to a method for determining the total clotting activity of a blood or plasma sample, characterized in that a highly specific, reversible thrombin inhibitor is added to a blood or plasma sample in a defined amount, the clotting of the blood or p... | 04/24/2012 |
| 8133696 | Method for determining thrombin activity Methods and kits to determine thrombin activity are provided. They have the great advantage that there is no need to measure the whole calibrator curve in each individual medium, since a single-point measurement is adequate. ... | 03/13/2012 |
| 8058023 | Assessment of cardiac health and thrombotic risk in a patient The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery ... | 11/15/2011 |
| 8021854 | Method of treating vascular disease A method for attenuating the incidence and severity of endovascular disease, arrhythmias and malignancy via a reduction in the total circulating platelet volume is presented. The method will achieve the reduced rates of acute coronary syndromes observed in patients ... | 09/20/2011 |
| 7939288 | Method for differentiating between factor XIII deficiency states and fibrinogen deficiency states by means of thrombelastographic techniques The invention relates to a method for determining a factor XIII deficiency, a method for determining a fibrinogen deficiency, and a method for differentiating between a factor XIII deficiency and a fibrinogen deficiency by means of thrombelastographic techniques. On... | 05/10/2011 |
| 7935498 | Methods for identifying patients with increased risk of an adverse cardiovascular event Methods, compositions and kits are disclosed for identifying patients with an increased risk of experiencing an adverse cardiovascular event where the patient is undergoing aspirin antiplatelet therapy. A platelet-containing sample from the patient is evaluated for ... | 05/03/2011 |
| 7923217 | Specificity in the determination of antithrombin Methods and reagents for determining antithrombin III (AT) in body fluids by adding an AT binding partner to the sample and determining the free AT binding partner. ... | 04/12/2011 |
| 7906299 | Assay for low molecular weight heparin A prothrombin time reagent for determination of low molecular weight heparin in fresh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture in... | 03/15/2011 |
| 7803569 | Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations An arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII activating protease (FSAP) is described. In addition, diagnostic determination methods for detecting these mutants which are identified as risk factors are ... | 09/28/2010 |
| 7803570 | Method for determining the concentration of thrombin inhibitors The invention relates to a method for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid. It comprises the following steps. The body liquid is taken from a living body, and the body liquid is s... | 09/28/2010 |
| 7790410 | Method and apparatus for determining hemocompatibility Provided herein are techniques for screening materials for hemocompatibility. Hemocompatible materials may be advantageous when incorporated into devices that may come into direct contact with blood or other bodily fluids. Such techniques take advantage of conformat... | 09/07/2010 |
| 7790409 | Blood coagulation accelerator and container for blood examination The present invention provides a blood coagulation accelerator excellent under severe conditions at ordinary or higher temperatures and capable of exhibiting high blood coagulation performance stably over a long period of time, as well as a container for blood exami... | 09/07/2010 |
| 7785820 | Method for automatically determining the endogenous thrombin potential The present invention relates to a method for automatically determining the endogenous thrombin potential of a blood or plasma sample. ... | 08/31/2010 |
| 7759082 | Electroprocessed fibrin-based matrices and tissues The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may b... | 07/20/2010 |
| 7759083 | Screening method for a growth inhibitor or promoter of a vascular smooth muscle cell It was found that TAT which has not been known biological activity has a role as a new blood vessel smooth muscle proliferation factor, and then a screening method vascular of an inhibitor or promoter of a smooth muscle cell growth with TAT is established. ... | 07/20/2010 |
| 7727736 | Soluble phospholipids for use in clotting factor assays The present invention provides a soluble phospholipid reagent and assays of clotting activity using the same. The methods of the invention can be used to carry out any clotting assay or other assay of clotting activity that traditionally relies on platelet membranes... | 06/01/2010 |
| 7723064 | Methods for monitoring patients for efficacy of an antiplatelet therapy regimen Methods are disclosed for monitoring patients utilizing Mean Platelet Component values during therapeutic intervention. ... | 05/25/2010 |
| 7682808 | Coagulation and fibrinolytic cascades modulator A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker. ... | 03/23/2010 |
| 7595169 | Method for determining percent platelet aggregation A method for obtaining a percent aggregation or inhibition of platelets resulting from anti-platelet using a single blood sample is achieved. An assay device is provided. The assay device has multiple channels, each coupled to a common introduction port. A first pla... | 09/29/2009 |
| 7585642 | Methods for evaluating the quality of a heparin sample The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use are described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminogly... | 09/08/2009 |
| 7498146 | Stable factor VIII/von willebrand factor complex There are disclosed a stable factor VIII/vWF-complexes, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as methods of producing these complexes. ... | 03/03/2009 |
| 7494782 | Assay for measuring factor viia-antithrombin complexes A method for determining the concentration of factor VIIa-antithrombin complexes is disclosed which has application to estimating the level of intravascular exposure of tissue factor, assessing patient risk for hypercoagulation or other coagulopathies, and monitorin... | 02/24/2009 |
| 7442514 | Mutants of the factor VII-activating protease and detection methods using specific antibodies Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 160... | 10/28/2008 |
| 7439069 | Blood coagulation test cartridge, system, and method A system and method for determining a coagulation time, e.g., thrombin time, PT, aPTT, and ACT, of a blood sample deposited in a test cartridge is disclosed. The test cartridge includes a blood receptacle that is open to the atmosphere into which a blood sample is t... | 10/21/2008 |
| 7432352 | Hybrid molecules having Factor VII/VIIa activity The present invention relates to novel human coagulation Factor VII/VIIa proteins having coagulant potential/activity as well as pharmaceutical compositions comprising the proteins, uses thereof, and methods of treatment therewith. In particular, the present inventi... | 10/07/2008 |
| 7422905 | Blood coagulation test cartridge, system, and method A system and method for determining a coagulation time, e.g., TT, PT, aPTT, and ACT, of a test sample deposited in a test cartridge is disclosed. A cartridge housing having upper and lower major sides and a minor sidewall encloses a test chamber having a test chambe... | 09/09/2008 |
| 7399604 | Methods and products related to evaluating the quality of a polysaccharide The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use are described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminogly... | 07/15/2008 |
| 7399637 | Blood coagulation test cartridge, system, and method A system and method for determining a coagulation time, e.g., TT, PT, aPTT, and ACT, of a blood test sample deposited in a test cartridge is disclosed. A cartridge housing having upper and lower major sides and a minor sidewall encloses a test chamber having a test ... | 07/15/2008 |
| 7381536 | Assessment of cardiac health and thrombotic risk in a patient The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery ... | 06/03/2008 |
| 7378393 | Recombinant anticoagulant proteins Novel recombinant anticoagulation proteins, methods of their use and methods of their production are described. In particular, recombinant fusions of annexin V (ANV) and Kunitz protease inhibitors (KPI) that possess potent anticoagulant activity are provided. The fu... | 05/27/2008 |
| 7361306 | Device and method for measuring coagulation time and platelet activity The present invention refers to a novel device for measuring coagulation time and platelet activity wherein the patient can measure his or her coagulation time and platelet activity without the aid of medical professionals due to the fact that this device is fully a... | 04/22/2008 |
| 7361480 | Method and means for detecting gluten-induced diseases The invention is directed to a method of detecting gluten-induced diseases such as e.g. celiac disease and dermatitis herpetiformis. Said diseases are indicated by the presence of autoantibodies against tissue transglutaminase tTG in the blood The test is carried ou... | 04/22/2008 |
| 7357916 | Method for creating a uniform vascular wound in zebrafish or zebrafish larva Disclosed are improved methods for creating a uniform vascular wound in a zebrafish larva or zebrafish. The methods illustratively include subjecting a zebrafish larva to laser irradiation in an amount and for a period of time effective to cause a uniform vascular w... | 04/15/2008 |
| 7358337 | Assay for low molecular weight heparin A prothrombin time reagent for determination of low molecular weight heparin in frsh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture inc... | 04/15/2008 |
| 7357016 | Process and device for determining viscosity A process and a device for determining the viscosity of a fluid are proposed. Very simple and accurate determination is enabled in that the magnetic particles in the fluid are set into vibration by a magnetic field which varies over time. A measurement of the amplit... | 04/15/2008 |
| 7341697 | Reaction cell and operation method thereof A reaction cell is provided with a vessel-like cell main body and a circular piezoelectric/electrostrictive oscillator fixed to an outside of a bottom surface of the cell main body. The cell main body includes a circular bottom plate portion and a circumferential wa... | 03/11/2008 |
| 7332469 | Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions The present invention relates to methods of preventing or decreasing the severity of scarring in a subject comprising: obtaining a pharmaceutical composition comprising a single chain urokinase plasminogen activator molecule (scuPA) or a scuPA mimetic; and administe... | 02/19/2008 |
| 7332303 | Product quality enhancement in mammalian cell culture processes for protein production The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, illustratively, but not limited to, fed-batch cell cultures. The methods comprise feeding the cells with D-gal... | 02/19/2008 |
| 7323315 | Method for reducing effect of hematocrit on measurement of an analyte in whole blood A method for determining the presence and/or amount of an analyte in a sample of whole blood comprises the step of treating the sample with a nonlytic hypertonic salt composition to reduce the hematocrit by reducing the size of the red blood cells. In optical detect... | 01/29/2008 |
